1133P Additional practice-informing adverse event patterns and management in the KRYSTAL-1 phase II study of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC
Zhang, J., Leventakos, K., Leal, T.A., Pennell, N., Barve, M., Paulson, A.S., Bazhenova, L., Johnson, M.L., Chao, R.C., Velastegui, K., Qian, C., Bleker, W., Spira, A.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation
Weiss, J., Yaeger, R.D., Johnson, M.L., Spira, A., Klempner, S.J., Barve, M.A., Christensen, J.G., Chi, A., Der-Torossian, H., Velastegui, K., Kheoh, T., Ou, S-H.I.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
LBA24 KRYSTAL-1: Updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation
Klempner, S.J., Weiss, J., Pelster, M., Spira, A., Barve, M., Ou, S-H.I., Leal, T.A., Bekaii-Saab, T., Christensen, J.G., Kheoh, T., Velastegui, K., Torossian, H. Der, Yaeger, R.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article